Genomic antagonism between retinoic acid and estrogen signaling in breast cancer

Published on Thursday, 18 December 2014


Retinoic acid (RA) triggers antiproliferative effects in tumor cells, and therefore RA and its synthetic analogs have great potential as anticarcinogenic agents.

Retinoic acid receptors (RARs) mediate RA effects by directly regulating gene expression. To define the genetic network regulated by RARs in breast cancer, we identified RAR genomic targets using chromatin immunoprecipitation and expression analysis.

We found that RAR binding throughout the genome is highly coincident with estrogen receptor alpha (ERalpha) binding, resulting in a widespread crosstalk of RA and estrogen signaling to antagonistically regulate breast cancer-associated genes. ERalpha- and RAR-binding sites appear to be coevolved on a large scale throughout the human genome, often resulting in competitive binding activity at nearby or overlapping cis-regulatory elements.

The highly coordinated intersection between these two critical nuclear hormone receptor signaling pathways provides a global mechanism for balancing gene expression output via local regulatory interactions dispersed throughout the genome.



Supplemental Data - Document S1


Supplemental Data - Table S1

Supplemental Data - Table S2

Supplemental Data - Table S3

Supplemental Data - Table S4

Supplemental Data - Table S5

Supplemental Data - Table S6

Supplemental Data - Table S9


About this publication.